The Inhibitory Effects of Juglanin on Adipogenesis in 3T3-L1 Adipocytes
Authors Wang G, Wu B, Xu W, Jin X, Wang K, Wang H
Received 1 April 2020
Accepted for publication 23 September 2020
Published 2 December 2020 Volume 2020:14 Pages 5349—5357
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Qiongyu Guo
Guang Wang,1,* Bing Wu,2,* Wenzhou Xu,3 Xuefei Jin,4 Kun Wang,5 Heyuan Wang6
1Department of Intensive Care Unit, The First Hospital of Jilin University, Changchun, Jilin 130033, People’s Republic of China; 2Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, People’s Republic of China; 3Department of Periodontology, School and Hospital of Stomatology, Jilin University, Changchun, Jilin 130033, People’s Republic of China; 4Department of Urology, China-Japan Union Hospital of Jilin University, Jilin Key Laboratory of Urologic Oncology, Changchun, Jilin 130033, People’s Republic of China; 5Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, People’s Republic of China; 6Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130033, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Heyuan Wang
Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130033, People’s Republic of China
Email [email protected]
Introduction: Deregulation of adipogenesis plays an important role in obesity and other metabolism disorders. PPAR, C/EBP and SREBP1c are key transcriptional factors involved in adipogenesis and lipogenesis. Juglanin is a natural compound belonging to flavonoids, and it has been reported that juglanin has a potent inhibitory effect on inflammation and certain type of cancers. However, the effects of juglanin in adipogenesis have not been reported before.
Materials and Methods: 3T3-L1 preadipocytes were incubated with differentiation induction medium in the presence or absence of 0.5, 2.5, or 5 μM juglanin for an 8-day differentiation period. The lipid droplets accumulated in the cytoplasm were monitored by Oil Red O staining on days 0, 2, 5, and 8. The regulatory effects of juglanin on adipogenesis-related genes and proteins were investigated by real-time polymerase chain reaction and Western blot analysis.
Results: Juglanin significantly decreased lipid accumulation in differentiated adipocytes. Our findings show that juglanin reduced the expression of C/EBPα, C/EBPβ, and SREBP-1c without affecting PPARα or PPARγ expression. Additionally, juglanin increased the activation of the SIRT1/AMPK signaling pathway through the phosphorylation of AMPKα. Finally, we performed an AMPK inhibitor experiment, which revealed that the inhibitory effects of juglanin on adipogenesis are mediated through AMPK.
Discussion: Juglanin can prevent adipogenesis by suppressing lipid accumulation and the differentiation of preadipocytes. The mechanism of juglanin regulating adipogenesis requires further investigation. Future clinical study in vivo could shed more light on its implication in modulating obesity and metabolic disorders.
Keywords: Juglanin, adipogenesis, obesity, lipid metabolism, AMPK
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]